Table 3.
Subgroup analysis according to the type of thyroid dysfunction
| No thyroid irAE (N = 127) |
Thyroid irAE (N = 58) | ||||
|---|---|---|---|---|---|
| Newly developed overt hypothyroidism (N = 38) | Worsened hypothyroidism (N = 4) | Subclinical hyperthyroidism (N = 16) | P value | ||
| Age (years) a | 64.1 ± 11.2 | 65.0 ± 12.6 | 70.0 ± 8.8 | 69.9 ± 6.3 | 0.191 |
| Male, n (%) | 91 (71.7%) | 31 (81.6%) | 1 (25%) | 12 (75%) | 0.1003 |
| Death, n (%) | 64 (50.4%) | 11 (28.9%) | 2 (50%) | 6 (37.5%) | 0.119 |
| Treatment time b (month) | 4.0 ± 6.8 | 8.9 ± 8.0 | 11.0 ± 7.6 | 4.7 ± 7.1 | 0.001 |
| Period from initiation of ICI treatment to death (month) | 9.7 ± 10.0 | 15.4 ± 10.9 | 15.0 ± 11.9 | 12.0 ± 10.9 | 0.025 |
| Period from initiation of ICI treatment to diagnosis of irAE (month) | 9.7 ± 10.0c | 3.9 ± 5.3 | 1.0 ± 0.8 | 2.3 ± 5.7 | < 0.001 |
irAE immune related Adverse Event, BMI Body Mass Index, HCC Hepatocellular Carcinoma, ICI Immune check point Inhibitor
aAge at ICI initiation
bthe time from ICI treatment initiation date to last ICI treatment date
cIt is same as period from initiation of ICI treatment to death or last follow up because thyroid irAE did not occur